SQZ is a biotechnology company that develops and commercializes cell therapies for the treatment of cancer and autoimmune diseases.
Read moreAnnual Revenue
$24.5M
SQZ's revenue is the ranked 5th among it's top 10 competitors. The top 10 competitors average 23.2M. Over the last four quarters, SQZ's revenue has decreased by 36.8%. Specifically, in Q1 2022's revenue was $2.9M; in Q4 2021, it was $12.3M; in Q3 2021, it was $4.8M; in Q2 2021, SQZ's revenue was $4.5M.